TRS Biobank
Treatment-Resistant Schizophrenia Biobank (CRC Psychosis Study)
Cross-sectional biobank on treatment-resistant schizophrenia from Melbourne, built to search for biomarkers, with 3T structural, diffusion and resting-state brain MRI for a subset of patients, their relatives and healthy controls. Data go to approved, ethics-cleared projects.
Overview
The Treatment-Resistant Schizophrenia (TRS) Biobank was assembled by the Cooperative Research Centre for Mental Health together with the Melbourne Neuropsychiatry Centre at the University of Melbourne. Between 2012 and 2018 it gathered blood, brain MRI, neuropsychological and clinical information from adults in a single cross-sectional visit. Its purpose is the discovery of biomarkers for diagnosing schizophrenia, separating subtypes and predicting response to antipsychotics. After the CRC's term ended on 30 June 2018 the Department of Psychiatry became the custodian.
Composition
The record describes more than 200 participants over 18 years of age in three groups: people with schizophrenia, most of them taking clozapine when assessed (114 or more), first-degree relatives of these patients (33 or more), and unrelated people without a psychiatric diagnosis (67 or more). Neuroimaging exists for 135 or more participants. The record does not break the imaging subset down by group, and it gives no sex or age figures.
Acquisition
All MRI was acquired on a 3 T scanner and covers structural, diffusion tensor and resting-state functional imaging. The scanner vendor and sequence parameters are not stated in the public record. Alongside imaging, the biobank holds blood fractions (serum, plasma, platelets, red cells), a neuropsychological battery (IQ, set-shifting, working memory, spatial span) and clinical data on diagnosis, medication, symptoms, substance use, childhood trauma and nutrition.
Annotations
There are no image labels. Each participant carries a group (patient, relative or control) plus clinical and cognitive scores.
Known limitations
- The data are not openly accessible. Researchers apply with an ethics approval to the CRC Psychosis Study biobank committee, pay a cost recovery fee and must return the data they generate.
- All counts are lower bounds ("N = 135+"), so the exact size of the imaging subset is unknown.
- The figshare record is labelled with the AusGOAL Restrictive Licence Template, but no completed licence schedule is published; the binding terms are those of the access agreement form.
- The application form dates from 2016 and names CRC contacts, while the record says the CRC's term expired on 30 June
- Current access conditions must be confirmed with the University of Melbourne.
Cohort
Aggregate numbers from the sources below. Bars are relative to the 200 subjects.
Modality
- MRI 135 68%
Full description in Everall I, Pantelis C, Bousman C 2018, Treatment-Resistant Schizophrenia Biobank, University of Melbourne figshare
Condition
Groups can overlap
- Schizophrenia 114 57%
- Healthy control 67 34%
Full description in Everall I, Pantelis C, Bousman C 2018, Treatment-Resistant Schizophrenia Biobank, University of Melbourne figshare
License and access
Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer
A research proposal is reviewed and approved
CRC for Mental Health Biobank, CRC Psychosis Study (Treatment Resistant Schizophrenia cohort) Application and Access Agreement
Samples and data go to research projects approved by the biobank's scientific advisory committee, after ethics approval and an access agreement signed by the chief investigator and the institutional head. Access carries a cost recovery fee, data generated must be returned to the biobank, onward sharing needs permission, and publications acknowledge the CRC and are sent back as PDF.
What you can do
- Not stated
- Not stated
- Not stated
- Conditional
- Conditional
What you can share
- Conditional
- Not stated
- Share trained models Not stated
What you must do
- Yes
- Share alike No
- Yes
- Yes
- Manuscript review No
- Release code No
- Yes
- Not stated
Limits
- No re-identification Not stated
- Location limits No
Citation
Everall I, Pantelis C, Bousman C. Treatment-Resistant Schizophrenia Biobank. The University of Melbourne, dataset (2018). doi:10.4225/49/5a7936cc46b12. The access agreement also asks publications to acknowledge the CRC for Mental Health and the CRCMH Biobank.
Sources
Every number on this page comes from one of these documents. Each chart names the table or page it is taken from. The raw numbers are in stats.csv.